Replimune Announces Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 02 2019 - 8:00AM
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company
developing oncolytic immuno-gene therapies derived from its
Immulytic™ platform, announced that data with the Company’s lead
product candidate, RP1, will be presented at the upcoming Society
for Immunotherapy of Cancer (SITC) annual meeting in Washington,
D.C. from November 6-10, 2019. The poster which will be presented
on November 8, 2019 highlights results from the Phase 1 portion of
the Phase 1/2 clinical trial of RP1 as a single agent and in
combination with Opdivo® (nivolumab) in patients with solid tumors.
Details of Replimune’s poster presentation:
Abstract Title: Initial results of the phase 1
portion of an ongoing phase 1/2 study of RP1 as a single agent and
in combination with nivolumab in patients with solid tumors
Poster #: P433
Date: Friday, November 8, 2019, 7:00 a.m. ET –
8:00 p.m. ET
Location: Gaylord National Hotel &
Convention CenterAbout Replimune
Replimune Group Inc., headquartered in Woburn, MA, was founded
in 2015 to develop the next generation of “oncolytic immune-gene
therapies” for the treatment of cancer. Replimune is developing
novel, proprietary therapeutics intended to improve the direct
cancer-killing effects of selective virus replication and the
potency of the immune response to the tumor antigens released. The
Company’s Immulytic™ platform is designed to maximize systemic
immune activation, in particular to tumor neoantigens, through
robust viral-mediated immunogenic tumor cell killing and the
delivery of optimal combinations of immune-activating proteins to
the tumor and draining lymph nodes. The approach is expected to be
highly synergistic with immune checkpoint blockade and other
approaches to cancer treatment. Replimune intends to progress these
therapies rapidly through clinical development in combination with
other immuno-oncology products with complementary mechanisms of
action. For more information, please visit
www.replimune.com.
Opdivo® is a registered trademark of Bristol-Myers Squibb
Company
About RP1
RP1 is Replimune’s first Immulytic™ product candidate to enter
the clinic and is based on a proprietary new strain of herpes
simplex virus engineered to maximize tumor killing potency, the
immunogenicity of tumor cell death and the activation of a systemic
anti-tumor immune response.
Forward Looking Statements
This press release contains forward looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, including statements regarding our
expectations about our use of cash, our advancement of our clinical
trials, our goals to develop and commercialize our product
candidates, our plans to establish our own in-house manufacturing
capabilities, our proposed scientific presentations, and other
statements identified by words such as “could,” “expects,”
“intends,” “may,” “plans,” “potential,” “should,” “will,” “would,”
or similar expressions and the negatives of those terms.
Forward-looking statements are not promises or guarantees of future
performance, and are subject to a variety of risks and
uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those
contemplated in such forward-looking statements. These factors
include risks related to our limited operating history, our ability
to generate positive clinical trial results for our product
candidates, the costs and timing of establishing, equipping, and
operating our planned in-house manufacturing facility, the timing
and scope of regulatory approvals, changes in laws and regulations
to which we are subject, competitive pressures, our ability to
identify additional product candidates, and other risks set forth
under the heading “Risk Factors” of our Annual Report on Form 10-K
for the year ended March 31, 2019. Our actual results could
differ materially from the results described in or implied by such
forward-looking statements. Forward-looking statements speak only
as of the date hereof, and, except as required by law, we undertake
no obligation to update or revise these forward-looking
statements.
Replimune ContactPamela Esposito,
Ph.D.Replimune Group Inc.617.233.6988pamela@replimune.com
Investor Inquiries Chris BrinzeyWestwicke, an
ICR Company339.970.2843chris.brinzey@westwicke.com
Media InquiriesArleen Goldenberg Verge
Scientific
Communications917.548.1582agoldenberg@vergescientific.com
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Apr 2024 to May 2024
Replimune (NASDAQ:REPL)
Historical Stock Chart
From May 2023 to May 2024